How Effective Is the Vaccine for West Nile Virus?

The 4th Vaccine Conference 2012, sponsored by the Foreign Talent Information Research Center of the State Administration of Foreign Experts Affairs and China Pharmaceutical Biotechnology Association, and hosted by Biotec International Conference (Dalian) Co., Ltd., will be held in Beijing on March 26-28, 2012 .

2012 Fourth Vaccine Conference

This entry lacks an overview map . Supplementing related content makes the entry more complete and can be upgraded quickly. Come on!

The 4th Vaccine Conference 2012, sponsored by the Foreign Talent Information Research Center of the State Administration of Foreign Experts Affairs and China Pharmaceutical Biotechnology Association, and hosted by Biotec International Conference (Dalian) Co., Ltd., will be held in Beijing on March 26-28, 2012 .

Chinese name

2012 Fourth Vaccine Conference

City

Beijing

Hosting place

Beijing International Convention Center

Industry

Biology / Medicine / Health

City:	Beijing	Hosting place:	Beijing International Convention Center
start date:	March 26, 2012	End date:	March 28, 2012
Industry:	Biology / Medicine / Health

In addition to the main forum, the Vaccine Conference will organize global vaccination landscapes and prospects, breakthroughs in vaccine science and technology, vaccine research and development platforms based on cell biology and molecular biology, discovery and development of new human vaccines, and animal applications 8 science and technology forums and branch activities including vaccine production, vaccine development, clinical trial vaccine production, manufacturing and quality control / quality assurance.

The meeting was honored to invite Dr. Rene Labatut, Vice President of Global Technology of Sanofi-Pasteur, France, Dr. William Strohl, Vice President of Johnson & Johnson, Dr. Patrick Baeuerle, Chief Scientist of Micromet, Germany, Dr. Tilahun Yilma, Member of the American Academy of Sciences, and Senior of Novavax, USA Dr. John J. Trizzino, Vice President, Dr. Alan Liss, Director of the US Food and Drug Administration, Dr. Jonathan J Liu, R & D Director of MedImmune, USA, and Dr. Stephen Lockhart, Senior Vice President of Emergent BioSolutions in the UK, participated in the exchanges.

This conference will provide participants with cutting-edge scientific and technological information, relay industry development trends and latest trends, and is an annual event in the field of vaccine research.

Session 1: Global vaccination landscape and outlook

Topic 100: A new generation of vaccines looking ahead for decades

Topic 101: Development of universal and traveller vaccination against seasonal and influenza and major infectious diseases

Topic 102: Immunization programmes to eradicate poverty in developing countries

Topic 103: Key Vaccination Issues and Public Health in Developed Countries

Session 104: Evaluation of Vaccine Effectiveness and Safety, Durability, Safety of New Vaccines, Austin, Ethical Issues and Public Recognition

Session 2: Breakthroughs in Vaccine Science and Technology

Topic 210: Innate / Adaptive Immunization and Vaccine Design to Development

Session 211: Systems Biology, Genomics, and Proteomics for Vaccine Discovery and Development

Topic 212: Reverse Vaccines and Evidence-Based Vaccines

Session 213: Bioinformatics in Vaccines

Session 214: Application of Structural-Based Antigen Design in Vaccine Discovery

Session 215: Application of Biomarkers in Vaccine Discovery and Development

Topic 216: Controlling host pathogen interactions to make vaccines

Topic 217: Application of vaccines in personalized medicine

Topic 218: Application in animal models of vaccine development

Topic 220: Virus-like particles, nanotechnology and vaccines

Topic 221: General Vaccine Technology

Topic 222: Cytokine networks in vaccine design

Topic 223: Production of vaccines for genetically modified plants

Topic 224: TOLL-LIKE Receptor Vaccine Development Technology

Topic 225: Safety, cost, efficiency and impact of vaccination

Session 3: Vaccine R & D Platform Based on Cell Biology and Molecular Biology

Topic 300: Making better attenuated and inactivated vaccines

Topic 301: Immune boosters, vectors, adjuvants and vaccine design

Topic 302: Application of a Cell-Based Vaccine Technology Platform

Topic 303: New vaccine delivery technologies

Topic 304: Design and development of new subunit vaccines

Topic 305: Use of recombinant vector vaccines

Topic 306: Recombinant Nucleic Acid Vaccine Technology

Topic 307: Carbohydrate or polysaccharide vaccines

Topic 308: Peptide vaccines

Session 4: Discovery and Development of New Human Vaccines

Topic 410: Meningitis vaccine

Topic 411: Hepatitis Vaccines

Topic 412: HIV / AIDS / SIV vaccine development

Topic 413: Influenza and SARS vaccines

Topic 414: Dengue vaccine

Topic 415: Vaccines against rotavirus, chickenpox and shingles

Session 416: Ebola, Marburg, West Nile and Alphaviral Encephalitides vaccine development

Topic 417: Foot-and-Mouth Disease and Hanta virus vaccine development

Topic 418: Japanese Encephalitis, Junin, Hendra and Nipah Virus Vaccines

Special Topic 419: Measles, Tick-Bone Encephalitis Vaccine and Vaccines for Other Viral Infections

Topic 420: Molecular approaches to bacterial vaccines

Topic 421: Developing vaccines against super bacteria

Topic 422: Development of vaccines against Klebsiella and Streptococcus pneumoniae

Session 423: Shigella, Enterotoxigenic Escherichia coli and Urinary Pathogenic Escherichia coli Vaccines

Topic 424: Burkholderia pseudomallei and Burkholderia pseudomallei vaccines

Topic 431: Innovative R & D of Malaria Vaccine

Topic 432: Leishmaniasis and Leptospirosis vaccines

Topic 433: Antiprotozoal vaccines

Topic 434: Anti-Schistosomiasis and Toxoplasmosis Vaccines

Session 4-4: Development of new vaccines for adult prevention

Topic 4-5: Development of therapeutic vaccines against cancer

Session 4-6: Anti-inflammatory and Autoimmune Disease Vaccines

Topic 4-7: Development of vaccines against neurodegeneration and central nervous system

Topic 4-8: Therapeutic vaccines against addiction

Session 5: Vaccines for Animals

Topic 500: Recent breakthroughs in veterinary vaccines

Session 501: Lectures on Veterinary Vaccine Development by Leaders from Major Participants

Topic 502: Rapid vaccination to control zoonotic infectious diseases

Session 503: Introducing a New Generation of Veterinary Vaccines

Topic 504: Antiviral and antibacterial fish vaccines

Session 6: Development of clinical trials for vaccines

Topic 600: Evaluation of clinical efficacy and safety of vaccines

Topic 601: Thoughts on personalized medicine for clinical cancer vaccines

Topic 602: Clinical, disease control in response to public health events

Session 7: Production, manufacturing and quality control / quality assurance of vaccines

Session 8: Youth Forum

Session 8-1: Bioinformatics, Genomics, Proteomics in Vaccine Design Research

Session 8-2: Cell-based vaccine research for attenuated and inactivated research

Session 8-3: Research on Baculovirus / Insect Cell Expression Systems

Session 8-4: DNA / rDNA Vaccine Design and Generation

Topic 8-5: Research on vaccine conjugates, subunits, and adjuvants

Session 8-6: Studies on Immunity Legal, Safety, and Ethical Issues Nearing Public Acceptance

Session 9: Lectures and Training

Topic 900: How to Write a High-Quality SCI Journal Article

Topic 901: Preparation and prevention of pandemic influenza vaccine

Topic 902: How to implant a therapeutic vaccine in a hospital

Topic 903: Nursing and clinical management of vaccination side effects

1) Human vaccines: hepatitis B vaccine, hepatitis A vaccine, rabies vaccine, influenza vaccine, meningococcal vaccine, Japanese encephalitis vaccine, pneumonia vaccine, tuberculosis vaccine, AIDS vaccine, bird flu vaccine, cervical cancer vaccine rotavirus vaccine, SARS vaccine, etc .

2) Animal vaccines: animal vaccines such as dog vaccines, cat vaccines, vaccine production equipment, transportation equipment, storage equipment.

3) Poultry vaccines: chicken, duck, goose, pig, cattle, and sheep vaccines.

4) Others: vaccine testing equipment, vaccine research institutions, vaccine websites, books and periodicals.

In addition to the main forum, the Vaccine Conference will organize global vaccination landscapes and prospects, breakthroughs in vaccine science and technology, vaccine research and development platforms based on cell biology and molecular biology, discovery and development of new human vaccines, and animal applications 8 science and technology forums and branch activities including vaccine production, vaccine development, clinical trial vaccine production, manufacturing and quality control / quality assurance. The meeting was honored to invite Dr. Rene Labatut, Vice President of Global Technology of Sanofi-Pasteur, France, Dr. William Strohl, Vice President of Johnson & Johnson, Dr. Patrick Baeuerle, Chief Scientist of Micromet, Germany, Dr. Tilahun Yilma, Member of the American Academy of Sciences, and Senior of Novavax, USA Dr. John J. Trizzino, Vice President, Dr. Alan Liss, Director of the US Food and Drug Administration, Dr. Jonathan J Liu, R & D Director of MedImmune, USA, and Dr. Stephen Lockhart, Senior Vice President of Emergent BioSolutions in the UK, participated in the exchanges. It is estimated that the size of the conference will be 2,000 people and 100 exhibitors! This conference will provide participants with cutting-edge scientific and technological information, relay industry development trends and latest trends, and is an annual event in the field of vaccine research. Looking forward to seeing you in Beijing in March 2012!